Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Daiichi Sankyo’s HER3 ADC Posts Positive PII Data in 3rd Line NSCLC, US Filing Eyed by March
Daiichi Sankyo has unveiled favorable PII results for its antibody-drug conjugate (ADC) patritumab deruxtecan (HER3-DXd) for the third-line treatment of certain patients with EGFR-mutated non-small cell lung cancer (NSCLC). Based on the data, the company plans a US submission by…
To read the full story
Related Article
- Daiichi/Merck Pull HER3-DXd Filing for NSCLC in US
June 2, 2025
- Daiichi Sankyo’s HER3 ADC Hits PFS Goal in EGFR-Mutant Lung Cancer
September 18, 2024
- FDA Snubs Daiichi Sankyo’s HER3 ADC over Third-Party Manufacturing Issue
June 28, 2024
- Daiichi’s HER3 ADC Gets Priority Review in US for 3rd Line EGFR-Mutated NSCLC
December 26, 2023
- Daiichi Sankyo Rolls Out Lung, Breast Cancer Data for HER3-Directed ADC
March 22, 2023
- Daiichi Sankyo’s HER3 ADC Enters PIII for EGFR-Mutated NSCLC
August 10, 2022
- Daiichi Sankyo’s HER3-Directed ADC Shows Promise in Breast Cancer
June 7, 2022
- Daiichi Sankyo’s HER3 ADC Gets Breakthrough Therapy Tag in US
December 27, 2021
- Daiichi Sankyo’s ADC U3-1402 Scores 39% ORR for EGFR-Mutated NSCLC in PI
June 8, 2021
BUSINESS
- Shionogi to Lift Stake in ViiV to 21.7% as Pfizer Exits
January 21, 2026
- Fuji Pharma Earns Approval for High-Dose Stelara Biosimilar
January 21, 2026
- Kaken’s Hyperhidrosis Drug Ecclock Now Available in South Korea
January 20, 2026
- Daridorexant Hits Primary Goal in South Korea PIII Insomnia Trial, Nxera Plans Filing in Q1 2026
January 20, 2026
- Enhertu Combo Accepted for EU Review in First-Line HER2 Breast Cancer
January 20, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…